Edition:
United States

Auris Medical Holding AG (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Global Market

0.90USD
24 Mar 2017
Change (% chg)

$0.01 (+1.12%)
Prev Close
$0.89
Open
$0.90
Day's High
$0.92
Day's Low
$0.87
Volume
70,509
Avg. Vol
84,735
52-wk High
$5.44
52-wk Low
$0.66

Latest Key Developments (Source: Significant Developments)

Auris Medical expects 2017 operating expenses will be in range of chf 28 to 32 mln
Tuesday, 14 Mar 2017 06:01am EDT 

Auris Medical Holding Ag : Auris medical provides business update and reports full year 2016 financial results . Auris medical holding ag- expects that its operating expenses in 2017 will be in range of chf 28.0 to 32.0 million .Auris medical holding ag says with proceeds from february 2017 offering, company's cash runway has been extended into q1 of 2018.  Full Article

Auris Medical expands clinical development pipeline for vertigo treatment
Friday, 3 Feb 2017 06:31am EST 

Auris Medical Holding Ag : Auris Medical expands clinical development pipeline with intranasal betahistine for the treatment of meniere's disease and vestibular vertigo . Auris Medical Holding Ag - under product code am-125, to develop betahistine dihydrochloride in spray formulation . Auris Medical Holding Ag - entered into an agreement with otifex therapeutics pty. ltd. To purchase various assets related to intranasal betahistine .Auris Medical Holding Ag - plans to initiate a second phase 1 trial for intranasal betahistine in 2017.  Full Article

Auris Medical resumes enrollment in tactt3 phase 3 trial of Keyzilen
Thursday, 26 Jan 2017 08:04am EST 

Auris Medical Holding AG : Auris Medical resumes enrollment in tactt3 phase 3 trial of keyzilen in acute and post-acute tinnitus . Auris Medical Holding - amended protocol elevates tinnitus functional index score from a key secondary endpoint to an alternate primary efficacy endpoint . Auris Medical Holding AG - "we look forward to top-line results in early 2018" . Auris Medical Holding AG says amended protocol increases trial size with enrollment of an additional 60 patients in each of stratum A and B .Auris Medical Holding AG - amended protocol includes certain patient subgroups in confirmatory statistical testing.  Full Article

Auris Medical on track to resume enrollment of keyzilen tinnitus program
Tuesday, 6 Dec 2016 07:04am EST 

Auris Medical Holding AG: Auris Medical on track to resume enrollment of keyzilen tinnitus program following regulatory feedback . Auris Medical Holding AG - "we look forward to top-line results from tactt3's trial in early 2018" . Auris Medical Holding AG - through type c meeting, FDA confirmed , as per standard practice, 2 positive confirmatory trials would be required to submit NDA .Auris Medical Holding AG - in separate FDA meeting , alignment was achieved on key items of keyzilenchemistry, manufacturing, controls section for future NDA.  Full Article

Auris reports top-line results from TACTT2 trial with Keyzilen
Thursday, 18 Aug 2016 07:30am EDT 

Auris Medical Holding AG : Reports top-line results from TACTT2 trial with Keyzilen in acute inner ear tinnitus . Treatment with Keyzilen did not demonstrate statistically significant difference in tinnitus improvement versus placebo . TACTT2 trial did not meet its co-primary efficacy endpoints . Top-Line results from the phase 3 TACTT3 trial expected in the fourth quarter of 2016 . Keyzilen was well tolerated with no drug-related serious adverse events Further company coverage: [EARS.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Auris medical Q2 loss per share CHF 0.25
Thursday, 18 Aug 2016 07:21am EDT 

Auris Medical Holding AG : Auris Medical provides business update and reports second quarter 2016 financial results . Q2 loss per share CHF 0.25 . Continues to expect that its operating expenses in 2016 will be in range of CHF 33.0 to 38.0 million .Existing cash and cash equivalents, including $12.5 million loan, will enable funding of operations until year-end 2017.  Full Article

Auris Medical secures loan facility of up to $20 million
Tuesday, 19 Jul 2016 04:50pm EDT 

Auris Medical Holding Ag : Financing is in form of a 42-month loan bearing interest at a minimum rate of 9.55% per annum . Entered into a loan facility agreement with Hercules Capital, Inc for up to $20 million in financing . Auris Medical secures loan facility of up to $20 million . Issued Hercules warrant to purchase up to 241,117 shares of company's common stock at an exercise price of $3.94 per share .Terms include an initial interest-only period until June 30, 2017, which is extendable to march 31, 2018.  Full Article

Auris Medical says FDA granted fast track designation for Keyzilen
Monday, 18 Jul 2016 08:06am EDT 

Auris Medical Holding Ag : FDA grants Auris Medical fast track designation for keyzilen in acute peripheral tinnitus .Results from TACTT2 and TACTT3 trials are expected in August 2016 and in Q4 of 2016, respectively.  Full Article

Auris Medical completes enrollment of Phase 3 TACTT3 trial
Tuesday, 28 Jun 2016 08:11am EDT 

Auris Medical Holding Ag : Auris Medical completes enrollment of Phase 3 TACTT3 trial with Keyzilen in acute and post-acute inner ear tinnitus .Top-Line results from TACTT3 trial expected in Q4.  Full Article

Auris Medical initiates phase 3 trial of AM-111
Friday, 17 Jun 2016 08:08am EDT 

Auris Medical Holding Ag :initiates phase 3 trial of AM-111 for treatment of sudden deafness.  Full Article

More From Around the Web